OCD Clinical Trial
Official title:
Neuromodulation for a Novel OCD Biomarker and Treatment
Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | August 31, 2026 |
Est. primary completion date | August 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: (1) a primary DSM-5 diagnosis of OCD, (2) a score of 16 or greater on the YBOCS (3) at least 18 years of age; and (4) willingness and ability to provide informed consent and comply with the requirements of the study protocol. Exclusion Criteria: (1) a lifetime history of bipolar or psychotic disorders; (2) history of Tourette syndrome; (3) psychosurgery; (4) substance abuse or dependence (other than nicotine) in the past 3 months; (5) organic brain syndrome, mental retardation or other potentially interfering cognitive dysfunction; (6) severe depression (MADRS score of 30 or greater); (7) suicidal risk as determined by moderate or greater score on the Columbia Suicide Severity Rating Scale (C-SSRS); (8) pregnancy or lactation; (9) changes to pharmacotherapy for OCD or the initiation of cognitive-behavior therapy within the last 3 months; and (10) specific to the tACS and EEG procedures no metal implants in head, any implanted electronic devices, any skin sensitivity, color blindness or impaired vision despite correction, claustrophobia, and any history of epilepsy or neurological disorder. |
Country | Name | City | State |
---|---|---|---|
United States | Boston University Center for Anxiety and Related Disorders (BU-CARD) | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston University Charles River Campus |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | YBOCS | There are 10 YBOCS questions scored 0 to 4. The total Y-BOCS score is the sum of items 1-10. A higher score is worse. | day 5 of intervention | |
Secondary | YBOCS | There are 10 YBOCS questions scored 0 to 4. The total Y-BOCS score is the sum of items 1-10. A higher score is worse. | 1 month after intervention | |
Secondary | YBOCS | There are 10 YBOCS questions scored 0 to 4. The total Y-BOCS score is the sum of items 1-10. A higher score is worse. | 2 months after intervention | |
Secondary | YBOCS | There are 10 YBOCS questions scored 0 to 4. The total Y-BOCS score is the sum of items 1-10. A higher score is worse. | 3 months after intervention | |
Secondary | EEG beta-gamma rhythms | day 5 of intervention | ||
Secondary | EEG beta-gamma rhythms | 1 month after intervention | ||
Secondary | EEG beta-gamma rhythms | 2 months after intervention | ||
Secondary | EEG beta-gamma rhythms | 3 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00215137 -
Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
|
Phase 2 | |
Recruiting |
NCT06050369 -
Objective Characterizatoion of Repetitive Behaviors
|
N/A | |
Recruiting |
NCT06347978 -
Personalized DBS for OCD Guided by Stereoencephalography Mapping
|
N/A | |
Withdrawn |
NCT03926546 -
Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT05712057 -
Neurostimulation Versus Therapy for Problems With Emotions
|
N/A | |
Not yet recruiting |
NCT03313622 -
Locating Biomarkers in OCD Through Behavioral Tasks
|
||
Withdrawn |
NCT03842345 -
DELPhI Evaluation of Psychiatric Conditions
|
||
Completed |
NCT02866422 -
Development of an Instrument That Monitors Behaviors Associated With OCD
|
N/A | |
Completed |
NCT01833442 -
Randomized Controlled Meditation Trial for Treating OCD
|
N/A | |
Recruiting |
NCT04904952 -
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
|
N/A | |
Completed |
NCT05981690 -
Therapist Guided, Parent-led, Cognitive Behavioural Therapy (CBT) for Preadolescent Children With Obsessive Compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT02500888 -
Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT06244121 -
Effect of Pyridoxine as Add-on Therapy in OCD Patients
|
N/A | |
Recruiting |
NCT05580614 -
Paired tVNS With ERP in OCD
|
N/A | |
Active, not recruiting |
NCT03511534 -
Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT05624528 -
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
|
Phase 2 | |
Recruiting |
NCT05881356 -
Discovering Factors in the Clinical Study Journey of Patients With OCD
|
||
Recruiting |
NCT05359562 -
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
|
N/A | |
Recruiting |
NCT03459456 -
Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)
|